Kymera Therapeutics, Inc.
KYMR evidence brief
What we can confirm
- BioSniper Score:
- 4.5 / 10
- Market Cap:
- $9.68B
- Lead Asset:
- KT-253 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for KYMR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KYMR
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule degraders for immunological diseases, with a lead STAT6 degrader in Phase 2b trials and partnerships with Sanofi and Gilead.
Key risk: Clinical trial failure
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 6 clinical trials · 1 catalyst for Kymera Therapeutics, Inc..
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule degraders for immunological diseases, with a lead STAT6 degrader in Phase 2b trials and partnerships with Sanofi and Gilead.
- Cash & equivalents of $124.5M as of 2026-06-30 [sec].
- Total revenue of $65.0M and net loss of -$61.2M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $1,509.3M as of 2026-06-30 [sec].
- KT-621 (STAT6 degrader) Phase 2b atopic dermatitis trial completed enrollment; topline data expected by year-end 2026 [news].
- Strategic collaboration with Gilead on CDK2 molecular glue degraders; Gilead exercised option to license KT-200 [sec_mda].
What works
- KT-621 is a first-in-class oral STAT6 degrader with completed Phase 2b enrollment in atopic dermatitis and topline data expected by year-end 2026, positioning it for potential Phase 3 initiation in mid-2027 [news].
- Partnerships with Sanofi (IRAK4 degrader KT-485) and Gilead (CDK2 molecular glue) provide non-dilutive funding and validation of platform [sec].
- Raised approximately $980.7M in gross proceeds from equity offerings, extending cash runway into 2029 [sec].
What to weigh
- Accumulated deficit of $1,196M as of June 30, 2026, reflecting substantial cumulative losses [sec_mda].
- Net loss of -$61.2M for the six months ended June 30, 2026, with expectations of increasing expenses for clinical trials and potential commercialization [sec].
- No approved products or recurring revenue from product sales; future funding needs remain significant and uncertain [sec_mda].
From the filings
Quoted directly from source documents.
KT-621 Phase 2b atopic dermatitis trial enrollment completed; topline data expected by year-end 2026.
“Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026”
News · September 1, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline — Topline data from KT-621 Phase 2b atopic dermatitis trial expected by this date.
Risks & what to watch (3)›
Key risks
- Clinical trial failure — KT-621 Phase 2b topline data due year-end 2026; negative results could impair pipeline value [news].
- Cash runway dependency — Cash of $124.5M as of 2026-06-30 may not cover increasing R&D and commercialization costs [sec].
- No approved products — Company has no marketed products; revenue depends on partnerships and future sales [sec_mda].
What to watch
- KT-621 Phase 2b atopic dermatitis topline data expected by year-end 2026 [news].
- KT-621 Phase 2b asthma trial topline data expected in late 2027 [news].
- Gilead's IND filing for KT-200 expected in 2027 [sec_mda].
- Sanofi's clinical testing of KT-485 (IRAK4 degrader) in 2026 [sec].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Kymera Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kymera Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.09 · 0% dilution
Lead: Phase 1
2 candidates
1 upcoming, next in ~78d
0 buys · 160 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 19, 2026- % of float
- 15.3%
- Days to cover
- 14.5
- Shares short
- 10,402,722
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KYMR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Kymera Therapeutics, Inc.?
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule degraders for immunological diseases, with a lead STAT6 degrader in Phase 2b trials and partnerships with Sanofi and Gilead.
What is Kymera Therapeutics, Inc.'s lead drug candidate?
Kymera Therapeutics, Inc.'s most advanced tracked candidate is KT-253 (Phase 1) for Treatment of relapsed or refractory high grade myeloid malignancies, acute lymphocytic leukemia (ALL), lymphomas, and solid tumors; orphan designation for acute myeloid leukemia.
What is Kymera Therapeutics, Inc.'s next catalyst?
Kymera Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase2_Topline: 0001193125-26-281817" — expected December 31, 2026.
Who is the CEO of Kymera Therapeutics, Inc.?
Dr. Nello Mainolfi M.D., Ph.D. is the chief executive officer of Kymera Therapeutics, Inc. (KYMR).
Where is Kymera Therapeutics, Inc. headquartered?
Kymera Therapeutics, Inc. (KYMR) is headquartered in Watertown, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.